Gilead Sciences, Inc.
GILD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $137,973 | $138,033 | $139,614 | $115,278 |
| - Cash | $9,354 | $5,144 | $7,926 | $9,991 |
| + Debt | $2,806 | $24,946 | $24,952 | $27,322 |
| Enterprise Value | $131,425 | $157,835 | $156,640 | $132,609 |
| Revenue | $7,769 | $7,081 | $6,667 | $7,569 |
| % Growth | 9.7% | 6.2% | -11.9% | – |
| Gross Profit | $6,200 | $5,580 | $5,127 | $5,988 |
| % Margin | 79.8% | 78.8% | 76.9% | 79.1% |
| EBITDA | $4,583 | $3,374 | $2,605 | $3,109 |
| % Margin | 59% | 47.6% | 39.1% | 41.1% |
| Net Income | $3,052 | $1,960 | $1,315 | $1,783 |
| % Margin | 39.3% | 27.7% | 19.7% | 23.6% |
| EPS Diluted | 2.43 | 1.56 | 1.04 | 1.42 |
| % Growth | 55.8% | 50% | -26.8% | – |
| Operating Cash Flow | $4,108 | $827 | $1,757 | $2,975 |
| Capital Expenditures | -$147 | -$107 | -$104 | -$147 |
| Free Cash Flow | $3,961 | $720 | $1,653 | $2,828 |